The Avalo Therapeutics Inc (NASDAQ: AVTX) stock price rallied 18.7% as of 8:15 EST despite the lack of news releases from the clinical-stage biotechnology company. The last significant announcement from Avalo was on August 3, 2023, when it released its Q2 2023 financial results.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The company has yet to make any significant announcements leaving it susceptible to investor sentiment. Today’s rally can be attributed to positive investor sentiment, given that over 16.54 million AVTX shares had changed hands at writing.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Top Broker Recommendation
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
A critical highlight of the Q2 2023 financial report was the failure of its PEAK trail to meet its primary endpoints, as reported on June 26, 2023. The trial miss triggered a massive decline in Avalo’s share price, which it has never recovered.
Dr Garry Neil, Avalo Therapeutics’ CEO and Chairman, said: “Although the PEAK trial did not meet its primary endpoint, mechanistically, I believe AVTX-002 has promise in other inflammatory-driven diseases, including IBD and other diseases of the lung, gut and skin. Additionally, we believe an opportunity remains in asthma, particularly in a subset of patients with higher baseline LIGHT levels.”
“We also have high confidence in our preclinical stage fully human BTLA agonist fusion protein (AVTX-008) to potentially treat a wide range of autoimmune diseases and are excited by the drug’s novel mechanism of action and potential usage in patients not responsive to anti-TNF therapy. The team is working tirelessly to determine the best path forward for these assets, including indication selection and funding to support development.”
The influx of new buyers into AVTX stock is a good sign that it could still turn things around and recoup some of its losses from the PEAK trial topline results. Other quarterly report highlights include Avalo prepaying $6 million of principal under its loan and security agreement in June 2023.
Avalo entered into a forbearance agreement with its debt lenders, under which they agreed that a default event had occurred due to a material adverse change in the Company’s business, and the lenders agreed to forbear from enforcing its complete remedies. The company was given relief up to August 15, 2023.
Avalo Therapeutics (AVTX) stock price.
The Avalo Therapeutics (AVTX) stock price rallied 18.69% to trade at $0.1740, from Thursday’s closing price of $0.14466.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.